cisplatin + vindesine

Cisplatin + vindesine is a combination chemotherapy regimen consisting of two cytotoxic agents, cisplatin and vindesine. Cisplatin is a platinum-based compound that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. Vindesine is a vinca alkaloid that inhibits microtubule assembly, thereby disrupting mitosis. This combination has been primarily investigated for the treatment of advanced non-small cell lung cancer (NSCLC), including squamous carcinoma and adenocarcinoma, in patients who have not previously received chemotherapy. Clinical studies have shown response rates around 43% for complete and partial remissions, with higher doses of cisplatin associated with longer median duration of response and survival compared to lower doses. The main toxicities are peripheral neuropathy and moderate azotemia; myelosuppression is generally not dose-limiting[1][2][4].